08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Information collected in employment or business-to-business contexts is exempt for one year. For th...
Read More >
CONVERGE is in its 4th year of bringing together the world’s leading companies for 2 days of dynami...
Read More >
After months of drama that we dutifully catalogued right here, the U.S. plan to “force the sale of ...
Read More >
How You Should Deal With Missing Plan Participants. What you need to do. Being a 401(k) plan spons...
Read More >
On May 21, the SEC finalized amendments to its rules and forms revising the disclosure requirements ...
Read More >
It's the end of the year and while everyone is busy, employers in California should be aware of new ...
Read More >